One in Six Billion podcast

A podcast about diabetes and genes

With Andrew Hattersley
and Maggie Shepherd

Series 3 episode 6. Gill Preston, Gill Spyer, and Ali Chakera The challenge of diagnosing and managing glucokinase MODY in pregnancy

Posted by Design Studio

Released 19 December 2024
In this episode we talk to Gill Preston, who was active and slim, when she was diagnosed with gestational diabetes in pregnancy. Her raised fasting glucose did not come down with tablets or insulin. Luckily she met Andrew Hattersley in the clinic, who recognised she had glucokinase MODY. Gill Spyer, working during her PhD showed that in glucokinase pregnancy the size of the baby depended on whether they inherited the genetic change from the mother and was not altered by insulin treatment. When the baby had the mutation it would grow normally and no treatment of the mother was needed.

Ali Chakera continued research into glucokinase pregnancy; his research showed that slim women (BMI <25) with a raised fasting glucose of above 5.5mmol/l had a 1 in 3 chance of having GCK MODY and should be tested. He also looked into genetic testing the fetus directly, through a blood sample taken from the mother, rather than trying to infer from fetal growth on ultrasound.

Gill Preston is a Mum of two boys and works at the University of Exeter. She was tested for diabetes when pregnant due to her age and family history of Type 2 diabetes in her father.  Her fasting blood glucose levels were consistently high, around 6mmol/L and she was fortunate to meet Andrew Hattersley in clinic during her second pregnancy who suspected GCK MODY and organised genetic testing which confirmed that diagnosis. This diagnosis was reassuring for Gill and meant she did not require any ongoing treatment for that raised blood glucose.

Gill Spyer is a consultant diabetologist at Torbay hospital in Devon. She previously worked in Exeter and undertook a PhD specifically focusing on women with GCK MODY who were pregnant. This was an exciting area as we’d previously shown the impact of a GCK mutation on birth weight. Gill’s research included looking at the impact of fetal genotype and treatment on birthweight. She was able to show that the birthweight of the baby was altered by whether, or not, they had inherited the GCK genetic change as opposed to any treatment they were given. She also investigated the effect of lowering blood glucose in individuals with GCK MODY, compared to controls and those with Type 2 diabetes and showed that those with GCK mutations, had hypoglycaemic symptoms at higher levels of blood glucose and needed more insulin to make any impact on their blood glucose levels.

Ali Chakera is a consultant diabetologist working in Brighton. He also undertook a PhD in Exeter, focusing on GCK MODY and GCK in pregnancy. He wanted to raise awareness of GCK MODY through antenatal clinics and conducted a study to show that 1 in 1000 women had GCK MODY. He wanted to improve the odds of identifying these women and his research showed that 2 main factors were key in identifying those with GCK MODY in pregnancy: a BMI of 25 or less and a fasting glucose of >5.5mmol/L with the chances of identifying GCK MODY then improved to 1 in 3 using those criteria. He was also recruiting patients in pregnancy clinics to identify whether a test could be developed to identify whether, or not, the baby had inherited the affected gene or not (which we will hear more about in the next episode).

More information can be found in the following publications:

This paper shows offspring of women with GCK mutations are at increased risk of macrosomia and its obstetric consequences. Fetal birth weight is predominantly altered by fetal genotype and not treatment of maternal hyperglycaemia with insulin.

Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation – PubMed

The following paper highlights which routine clinical criteria can be used to identify which women should be tested for GCK-MODY in pregnancy.

The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort – PubMed

Summaries about GCK (glucokinase) MODY for patients and their healthcare workers can be found on our website here https://www.diabetesgenes.org/what-is-mody/what-is-glucokinase-gck/

A good medical and scientific overview of glucokinase MODY and all the research done on it is this review article written by the Exeter team here

https://diabetesjournals.org/care/article/38/7/1383/30805/Recognition-and-Management-of-Individuals-With